Alpha-galactosylceramide for graft vs host disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Oct 2025: Trial started, NCT07246031
  2. 24 Nov 2025: Trial registered, NCT07246031

The trials

NCT07246031: BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation

State
Under way
Phase
Phase 2
People
50 planned
Started
29 Oct 2025
Primary completion
30 Apr 2028
Arms
Safety run-in and Expansion
Results
None posted
  1. 29 Oct 2025: Trial started
  2. 24 Nov 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as BPC-2001.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.